SCHEMBL29796089

SCHEMBL29796089

Cc1c(Cl)cc(C(=O)O)cc1N(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.48
TSHR P16473 1/20 0.42
TPMT P51580 3/20 0.42
HCAR3 P49019 1/20 0.39
SRD5A2 P31213 1/20 0.38
PLAU P00749 1/20 0.38
HCAR1 Q9BXC0 2/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GPR35 Q9HC97 1/20 0.37
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23214050 1.00 TTR (0.48) TTRTSHRTPMTHCAR3SRD5A2
SCHEMBL1573147 0.82 TTR (0.62) TTRTSHRTPMTSRD5A2PLAU
SCHEMBL29796165 0.81 CA12 (0.43) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL23213813 0.81 CA12 (0.43) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL8742151 0.78 TTR (0.48) TTRTPMTHCAR3HCAR1ALDH1A1
SCHEMBL8742186 0.77 TPMT (0.63) TTRTSHRTPMTPLAUALDH1A1
SCHEMBL3469681 0.76 TTR (0.56) TTRTSHRTPMTSRD5A2PLAU
SCHEMBL10300670 0.76 TTR (0.56) TTRTSHRTPMTSRD5A2PLAU
SCHEMBL10687512 0.76 TSHR (0.59) TTRTSHRHCAR3SRD5A2ALDH1A1
SCHEMBL8742109 0.76 TTR (0.50) TTRTSHRTPMTSRD5A2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2022200857-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2022-09-29 WO disclosed
EP-4041231-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2022-08-17 EP disclosed